Stockscreener 앱 받기
47.88
3.58%
1.625
전일 마감가:
$46.25
열려 있는:
$48.19
하루 거래량:
14.26M
Relative Volume:
0.95
시가총액:
$97.48B
수익:
$48.03B
순이익/손실:
$6.05B
주가수익비율:
16.17
EPS:
2.9615
순현금흐름:
$15.30B
1주 성능:
+2.34%
1개월 성능:
+9.30%
6개월 성능:
+2.25%
1년 성능:
-18.63%
1일 변동 폭
$47.60
$48.62
1주일 범위
$45.27
$48.62
52주 변동 폭
$42.52
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
47.88 | 94.15B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,063.22 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.57 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
230.07 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.58 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.44 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study - Benzinga
Bristol Myers (BMY) Sees Stock Surge on Positive Drug Trial News - GuruFocus
Prudential Financial Inc. Purchases 2,334,421 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Cantor Fitzgerald reiterates neutral rating on Bristol-Myers stock - Investing.com India
Cantor Fitzgerald maintains Bristol-Myers Squibb stock rating, cites milvexian potential - Investing.com India
Novo Nordisk, Bristol-Myers and Uber rose premarket; Performance Food falls - Investing.com
Heron Bay Capital Management Has $977,000 Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Mufg Securities Americas Inc. Purchases 9,182 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
14,187 Shares in Bristol Myers Squibb Company $BMY Acquired by Neo Ivy Capital Management - MarketBeat
Brandywine Global Investment Management LLC Sells 633,786 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Legal & General Group Plc Sells 707,829 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Crashes Again: Another Trial Failure Shocks Investors - Smartkarma
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Benzinga
Texas Attorney General Ken Paxton Sues Sanofi, Bristol-Myers Squibb - Hoodline
Quilter Plc Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Has $106.03 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb stock holds steady as BMO reiterates $47 target By Investing.com - Investing.com South Africa
Bristol-Myers Squibb: Navigating Challenges in a Critical Transition Phase - Ad-hoc-news.de
Texas Sues Bristol-Myers For Alleged Drug Misrepresentations - Law360
Merck, Bristol Myers Squibb plan NJ layoffs (updated) - NJBIZ
State of Texas Sues Bristol-Myers Squibb and Sanofi for Deceptive Marketing of Blood Thinner Plavix - cnhinews.com
Texas sues Bristol Myers, Sanofi for concealing blood thinner Plavix's alleged ineffectiveness - Reuters
Bristol-Myers, Sanofi Draw Texas Fraud Claims Over Plavix Safety - Bloomberg Law News
Bristol-Myers Squibb (BMY) Faces Legal Action Over Plavix Effectiveness Claims - GuruFocus
Bristol Myers, Sanofi sued by Texas over Plavix - Yahoo
What's Driving the Market Sentiment Around Bristol-Myers Squibb Co? - Benzinga
Buy Bristol Myers Squibb Stock. The Drugmaker Is Too Cheap to Ignore. - Barron's
Bristol-Myers Squibb stock holds steady as BMO reiterates $47 target - Investing.com India
Traub Capital Management LLC Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
2 Major Pharmaceutical Companies Laying Off Hundreds More In NJ - Patch
Vanguard Group Inc. Has $9.02 Billion Stake in Bristol Myers Squibb Company $BMY - MarketBeat
WBI Investments LLC Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance - Yahoo Finance UK
Primecap Management Co. CA Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb Company (BRM) stock a contrarian opportunityM&A Rumor & High Win Rate Trade Tips - newser.com
Pharma giant gave Irish employee three months to come up with €20,800 to cover alleged ‘overpayment’, WRC hears - The Irish Times
Bristol Myers Squibb Co. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Will Bristol Myers Squibb Company (BRM) stock beat growth indexesMarket Activity Summary & Fast Gain Swing Alerts - newser.com
Published on: 2025-11-19 14:34:44 - newser.com
Metabolic Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 576 Deals by Company A-Z, Therapy Focus and Technology Type - GlobeNewswire Inc.
Is Bristol Myers Squibb Company Celegne Contingent stock resilient in recession scenariosWeekly Gains Summary & Safe Entry Point Identification - newser.com
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance UK
Is Bristol Myers Squibb Company stock oversold or undervaluedJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Nordwand Advisors LLC Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Nomura Asset Management Co. Ltd. Boosts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Empowered Funds LLC Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Biokin/BMS’s Iza-bren Hits First Phase III OS Endpoint, Albeit In China - Citeline News & Insights
Will Bristol Myers Squibb Company Celegne Contingent stock benefit from mergersWeekly Investment Report & Free Risk Controlled Daily Trade Plans - newser.com
Bristol-Myers Squibb (BMY) Announces Early Results and Amendments to Cash Tender Offers - GuruFocus
How Bristol Myers Squibb Company stock reacts to new regulationsRate Cut & Verified Momentum Watchlists - newser.com
Bristol-Myers Squibb Can Appeal Pension Suit To 2nd Circ. - Law360
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
1.14%
자본화:
|
볼륨(24시간):